PDCD1 and neoplasm: One of the most promising targets is the programmed cell death-1 (PD-1) / programmed cell death ligand-1 (PD-L1) checkpoint pathway, which negatively regulates effector T-cell activity, inhibiting antitumor immune responses and thereby promoting tumor immune evasion [2, 3].